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characteristics. The checklist suggests that a quality network meta-analysis of 
this data should exclude one study with high risk of bias, avoid grouping sham 
procedures and optimal pain management, and control for baseline pain-score 
to address imbalance across arms. Meta-regression to control for differences in 
endpoint definitions or inclusion criteria would likely have been infeasible given 
the low number of studies. ConClusions: Applying the checklist improved our 
ability to identify sources of confounding to be addressed or highlighted as caveats 
in a meta-analysis.
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IMPleMentatIon of InteRnatIonal ChaRt RevIew StudIeS: an 
aSSeSSMent of Key deSIgn and oPeRatIonal ConSIdeRatIonS foR 
SuCCeSSful ConduCt
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objeCtives: There is an increased need to conduct international chart review 
studies (chart reviews) since health care databases with required information are 
not consistently available. Chart reviews offer an alternative for the effective cap-
ture and analysis of real-world patient-level data on patient characteristics and 
outcomes, treatment patterns, treatment effectiveness and safety. For successful 
implementation, awareness of significant multi-national design and operational 
considerations is necessary. Methods: A critical review of 13 recent chart reviews 
conducted in Europe and North America on treatment patterns, clinical outcomes 
and/or drug utilization and safety was undertaken. Design and operational chal-
lenges, opportunities, and learnings are delineated. Results: All studies collected 
data retrospectively. Two studies collected certain information prospectively. Four 
studies were categorized as post authorization safety studies. Therapeutic areas 
varied across the studies with 8 studies being in oncology. Sample size ranged 
from 20-2,000 patients, number of countries ranged from 1-6, and number of sites 
ranged from 4-375. All studies included at least 1 European country. Across studies, 
key design considerations include confirming the eligibility and study periods that 
permit evaluations of recent care patterns yet allow for sufficient follow-up time, 
case ascertainment and sampling frame methodologies, and safety reporting in the 
context of retrospective source data. Additionally, key operational considerations 
include balancing science and practicality in site selection, ambiguous multina-
tional ethical/regulatory requirements, country variations for informed consent, 
data collection designed to minimize site burden, and effective yet cost-efficient site 
management for quality data. ConClusions: International chart reviews are prov-
ing to be an effective methodology for capturing tailored, patient-level data. These 
studies can be used to address a myriad of research objectives. Through conduct 
and assessment of recent chart reviews, the design and operational considerations 
involved can be understood with opportunities for improvement learned. These 
lessons will help for better planning and overcoming these challenges.
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StudIeS
Vinken A.1, Lis Y.2, Coward G.2
1PAREXEL International, Amsterdam, The Netherlands, 2PAREXEL International, Uxbridge, UK
objeCtives: Some observational studies fail to gain momentum while others move 
smoothly to successful completion. This study set out to determine which factors 
drive physician motivation in prospective observational studies. Methods: A web 
based survey was designed using input from structured literature review, investiga-
tors and experienced observational study researchers. It comprised 35 questions 
covering: Scientific and clinical factors (7), Study requirements (11), Operational 
considerations (6), Financial and legal considerations (4), Personal and professional 
factors (7). Respondents were asked to rate factors on a scale -5 to +5 (+5 represented 
very motivational and -5 very de-motivational). Free form comments were also 
invited. The survey was e-mailed to investigators (n= 1160) identified from Citeline® 
as having performed both prospective observational studies and clinical trials in the 
last 5 years. Results: Overall response was 15% (n= 174), Europe (55%) and North 
America (45%) covering Community care (34%), University hospitals (29%), General 
hospitals (24%) and dedicated research facilities (13%). Most respondents had experi-
ence of > 5 clinical trials in the last 5 years (81%) but fewer had similar experience 
with observational studies (40%). Responses indicate that not all physicians are 
equally motivated by the same factors. However most important motivational fac-
tors were in the scientific and clinical, financial and legal domains including studies 
which advance medical knowledge and / or patient management and acceptable 
honoraria. Less important factors were in the personal and professional domain 
including opportunities to speak at conferences or publish the data. Investigators 
more experienced in observational research placed greater motivational value on 
advancing medical knowledge and/ or patient management than less experienced 
colleagues. ConClusions: The findings provide good insight into which factors 
really motivate physicians and more customised motivational approaches are likely 
to minimise study risks. Further sub analyses of the survey data may identify more 
detailed strategies to pursue.
PRM212
ReSeaRCh In haeMoPhIlIa B – StudIeS In a RaRe dISeaSe In tIMeS of 
RequIReMentS foR hIgh evIdenCe levelS
Schopohl D.1, Berger K.1, Schramm W.2
1University Hospital of Munich, Muenchen, Germany, 2Rudolf-Marx-Stiftung, Bluterbetreuung 
Bayern, Muenchen, Germany
objeCtives: Haemophilia B (HB), a rare disease, occurs in approximately 1:30,000 
males and requires individualized therapy with factor IX (FIX) concentrate. Payers 
in European countries request studies with high levels of evidence for decision 
making. The objective was to determine the status quo of current studies con-
cerning HB, new FIX products and new therapeutic modalities regarding clinical 
and real-life evidence. Methods: A systematic literature research was conducted 
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Detrusor overactivity (DO) is characterised by the symptoms of overactive bladder 
(OAB) including incontinence, urgency, and voiding episodes; though, identifica-
tion of a cardinal symptom still remains unclear, where treatment efficacy is often 
evaluated across multiple outcomes. As a result, ascertainment of the most patient 
impacting symptom is crucial. Joint modelling allows us to evaluate the association 
between surrogate outcome measures such as patients’ symptom profiles and time 
to perceived treatment failure. objeCtives: To determine the most associated OAB 
symptom with patients’ perceived time of treatment failure using a novel applica-
tion of a joint modelling framework. Methods: To account for the potential cor-
relation between symptoms, we applied a joint model of multivariate longitudinal 
and time-to-event data to a randomised clinical trial of patients receiving botulinum 
toxin for DO. We investigate the association of incontinence, urgency and voiding 
episodes collected at baseline, 6 weeks, 3 months, and 6 months, on patients’ per-
ceived time of treatment failure. Results: The multivariate joint model was applied 
to 122 patients (270 data points) with 69 (56.6%) patients reporting treatment failure. 
The results identified urgency as the most impactful surrogate measure on patients’ 
perceived time of treatment failure, with an estimated hazard ratio of 1.26 (95% CI: 
0.97 to 1.64) for every additional urgency episode. Incontinence, voiding episodes 
and the interaction between symptom measures had a non-significant association. 
However, in this example, sensitivity to the model choice produced inconsistent 
estimates due to the limited nature of the data set and therefore results should be 
interpreted cautiously. ConClusions: This approach illustrates the advantage of 
applying a joint modelling framework to identify symptoms most associated with 
time to treatment failure. With an increasing need to identify and assess core symp-
toms for varying medical conditions, the novel use of a joint modelling approach 
would appear to be extremely promising.
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objeCtives: Large translational research projects often have abstract objectives, 
such as reducing the burden of disease and health care costs from type-2 diabetes 
(T2DM). Such an abstract objective entails: i) a very large number of possible strate-
gies to reach the objective and ii) a lack of detailed data and high levels in uncer-
tainty. Currently, no methods to support project selection and resource allocation 
decisions in such a setting are available. Methods: As a case study, we supported 
a resource allocation decision for the remaining funds in a large Dutch translational 
research consortium with the aforementioned objective, and compared the results 
to the decision made at the start of the project. We used the problem structuring, 
model building methods from multi-criteria decision analysis to identify four dif-
ferent alternative research strategies, and a set of evaluation criteria. Consequently, 
we used a combination of judgment from experts involved in the project and pre-
viously published data on the burden of disease and health care costs to evalu-
ate the alternatives. Finally, a decision analysis was performed using Stochastic 
Multicriteria Acceptability Analysis for ordinal data (SMAA-O), which allows for 
the combined use of quantitative and qualitative (ranked) data. Results: Using 
our method, it was decided to allocate remaining resources to the identification of 
biomarkers and development of technologies that can be used in the prevention of 
macrovascular complications in T2DM patients. This decision differed from the one 
made at the start of the project, which was not supported by any formal decision 
analysis. ConClusions: Our study shows that our method using SMAA-O can be a 
practical and valuable tool to support decisions on the allocation of research funds 
within large translational research consortia.
ReSeaRCh on MethodS – Study design
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ConfRontIng heteRogeneIty: uSIng SySteMatIC RevIew effeCtIvely 
foR Meta-analySIS
Quigley J.M., Woods B., Thompson J., Bryden P.A., Scott D.A.
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objeCtives: The pooling of treatment effects estimated from several trials via 
meta-analysis or network meta-analysis can be confounded by differences across 
studies; however, advanced methodologies are available to address many of these 
issues. Systematic reviews of interventions typically generate a large volume of 
data and lead to assimilation of a large amount of knowledge by the reviewers. 
Identifying key variances between trials can be difficult and important nuances 
can be missed by a meta-analyst. We have designed a novel checklist that high-
lights key areas of heterogeneity to be considered when designing and undertaking 
meta-analysis. Methods: It is important to identify differences early on; hence 
we have developed a checklist that can be applied to the results of a systematic 
review of randomised controlled clinical trials. Components of the checklist fall 
into four domains where heterogeneity may be present: population, interventions, 
outcomes, and risk of bias. Sections documenting the feasibility of network meta-
analysis and recommendations for analysis design are also included. The checklist 
has been retrospectively applied to a recent NICE technology appraisal; percuta-
neous vertebroplasty and percutaneous balloon kyphoplasty for the treatment 
of osteoporotic vertebral compression fractures (TA279). Results: The checklist 
identified the following sources of heterogeneity in the nine included studies: 
inclusion criteria, endpoint definitions, endpoint reporting, presence of cross-over, 
differences in interventions, risk of bias; and within-trial imbalances in baseline 
